SCHEMBL2460922

SCHEMBL2460922

CCCCCCCCC=CCCCCCCCC(=O)C(OP)C(O)CO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.52
DEGS1 O15121 1/20 0.49
TERT O14746 3/20 0.47
PTPN1 P18031 3/20 0.47
PPARG P37231 3/20 0.47
PPARD Q03181 3/20 0.47
PPARA Q07869 3/20 0.47
CYP1A2 P05177 2/20 0.47
MAPT P10636 2/20 0.47
CYP2C19 P33261 2/20 0.47
BLM P54132 2/20 0.47
HSD17B10 Q99714 2/20 0.47
FABP4 P15090 2/20 0.47
FAAH O00519 2/20 0.47
KMT2A Q03164 2/20 0.47
GMNN O75496 1/20 0.47
USP2 O75604 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29100618 1.00 DGKA (0.52) DGKADEGS1TERTPTPN1PPARG
SCHEMBL3239057 0.96 DGKA (0.49) DGKADEGS1TERTPTPN1PPARG
SCHEMBL26980074 0.96 DGKA (0.49) DGKADEGS1TERTPTPN1PPARG
SCHEMBL29100624 0.91 CES2 (0.46) MAPTKMT2ALMNADUSP3MEN1
SCHEMBL29100664 0.91 CES2 (0.46) MAPTKMT2ALMNADUSP3MEN1
SCHEMBL29100634 0.91 CES2 (0.46) MAPTKMT2ALMNADUSP3MEN1
SCHEMBL29100688 0.91 CES2 (0.46) MAPTKMT2ALMNADUSP3MEN1
SCHEMBL29100643 0.91 CES2 (0.46) MAPTKMT2ALMNADUSP3MEN1
SCHEMBL26980322 0.87 KMT2A (0.43) MAPTKMT2ALMNADUSP3MEN1
SCHEMBL26980812 0.87 KMT2A (0.43) MAPTKMT2ALMNADUSP3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018157107-A1 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING RESPIRATORY RELATED DISEASES AND CONDITIONS WITH XYLITOL-HEADGROUP LIPID ANALOGS NATIONAL JEWISH HEALTH (US) 2018-08-30 WO claimed
WO-2024097169-A1 TREATMENT OF CORONAVIRUS INFECTIONS WITH ANTIMICROBIAL PHOSPHOLIPID COMPOSITIONS NATIONAL JEWISH HEALTH (US) 2024-05-10 WO disclosed
EP-4284332-A1 ORAL LIPOSOMAL COMPOSITIONS Renault, Jean-Yves (FR) 2023-12-06 EP disclosed
CN-108431027-B Charge-reversed N-terminal spider silk protein domains and uses thereof 思百博技术股份公司 2022-07-22 CN disclosed
WO-2018157107-A1 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING RESPIRATORY RELATED DISEASES AND CONDITIONS WITH XYLITOL-HEADGROUP LIPID ANALOGS NATIONAL JEWISH HEALTH (US) 2018-08-30 WO disclosed
WO-2012061767-A2 DEFENSIN-LIKE MOLECULES AS NOVEL ANTIMICROBIAL AGENTS UNIVERSITY OF MARYLAND, BALTIMORE (US) 2012-05-10 WO disclosed
WO-2011109294-A1 LIPID DELIVERY FORMULATIONS DICERNA PHARMACEUTICALS, INC. (US) 2011-09-09 WO disclosed
EP-2142196-A2 SURFACTANT LIPIDS, COMPOSITIONS THEREOF, AND USES THEREOF National Jewish Health (US) 2010-01-13 EP disclosed
WO-2008121811-A2 SURFACTANT LIPIDS, COMPOSITIONS THEREOF, AND USES THEREOF NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) 2008-10-09 WO disclosed